Insight Genetics Licenses ALK Gene Mutations from St. Jude for Dx Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Insight Genetics today announced an exclusive worldwide licensing agreement with St. Jude Children's Hospital to develop a diagnostic test directed at the anaplastic lymphoma kinase, or ALK, gene to better monitor cancer patients and enable physicians to prescribe more effective treatments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.